Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-06-12Clinical Trial Update: Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma [EARLY_Phase 1]
An early-phase (Phase 1) clinical trial evaluating CT071 injections in high-risk, newly diagnosed multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-11Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]
Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.
-
FDA approval · 2024-06-11FDA Approved: POMALIDOMIDE — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s original (ANDA) application for pomalidomide, establishing a generic version of the drug. Pomalidomide is indica…
-
CLINICAL_TRIALS research · 2024-06-10Clinical Trial Update: PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications [NA]
This trial update describes PROSpECT-PRIOR-2-CHEMO, a study evaluating a prior dental intervention before chemotherapy to reduce chemotherap…
-
CLINICAL_TRIALS trial_result · 2024-06-06Clinical Trial Update: Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating panobinostat in combination with daratumumab, bortezomib, and dexamethasone for relapsed/refractory multiple myelom…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-31Clinical Trial Update: OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM [Phase 1, Phase 2]
Phase 1/2 clinical trial of OriCAR-017, a CAR-T cell therapy, for relapsed/refractory multiple myeloma, currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2024-05-31Clinical Trial Update: A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]
A Phase 3 trial evaluating alnuctamab versus standard-of-care regimens in relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial comparing Daratumumab, Bortezomib, and Dexamethasone (DVd) versus Bortezomib and Dexamethasone (Vd) in Chinese participants wi…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone [Phase 2]
A Phase 2 clinical trial evaluating induction, consolidation, and maintenance therapy with isatuximab, carfilzomib, lenalidomide, and dexame…
-
CLINICAL_TRIALS research · 2024-05-29Clinical Trial Update: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT [Phase 2]
A Phase 2 trial evaluates MIT-001 for prevention of oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation…
-
FDA approval · 2024-05-28FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for Tecvayli (teclistamab-cqyv) from Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2024-05-28Clinical Trial Update: Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer [Phase 1]
Phase 1 clinical trial evaluating the combination of sodium selenite with radiation therapy in patients with metastatic cancer.
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
This update reports the completion and posted results of a Phase 1/2 trial evaluating the safety and efficacy of the CAR-T therapy JCARH125 …
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma [Phase 1]
This update reports the completion of a Phase 1 study evaluating vactosertib in combination with pomalidomide for relapsed or relapsed/refra…
-
CLINICAL_TRIALS trial_result · 2024-05-24Clinical Trial Update: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy [NA]
A completed clinical trial evaluating the feasibility of a digital health coaching program for individuals after CAR T-cell therapy.
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation [Phase 4]
Phase 4 clinical trial evaluating the safety and efficacy of high-dose melphalan hydrochloride for injection in multiple myeloma patients un…
-
CLINICAL_TRIALS trial_result · 2024-05-22Clinical Trial Update: Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide [Phase 2]
A Phase 2 trial evaluating nivolumab in combination with daratumumab, with or without low-dose cyclophosphamide, for multiple myeloma has co…
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]
A completed Phase 1/2 trial of belantamab mafodotin in combination with either lenalidomide-dexamethasone or bortezomib-dexamethasone for re…
-
CLINICAL_TRIALS trial_result · 2024-05-17Clinical Trial Update: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
A completed Phase 1 study evaluated wild-type reovirus in combination with carfilzomib and dexamethasone for relapsed or refractory multiple…
-
FDA approval · 2024-05-16FDA Approved: IMDELLTRA (AMG757) — Original Application (Amgen, Inc)
FDA approved IMDELLTRA (AMG757) from Amgen via an original application; tarlatamab-dlle is approved for treating multiple myeloma.
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant [Phase 1, Phase 2]
A Phase 1/Phase 2 study of an investigational drug for multiple myeloma in patients who have relapsed after an allogeneic stem cell transpla…
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: MUK Nine b: OPTIMUM Treatment Protocol [Phase 2]
Phase 2 OPTIMUM treatment protocol update for MUK Nine b in multiple myeloma; the trial is currently ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study [Phase 1]
Phase 1 pilot study evaluating ixazomib with dexamethasone in patients with high-risk smoldering myeloma and multiple myeloma; the trial has…
-
CLINICAL_TRIALS trial_result · 2024-05-13Clinical Trial Update: Heart Rate Variability, Vagus Nerve and Cancer [NA]
The trial investigating heart rate variability and vagus nerve stimulation in cancer has been terminated. The listed conditions across the s…
-
EMA approval · 2024-05-13EMA Authorised: Plerixafor Accord (Plerixafor) — Accord Healthcare S.L.U.
EMA authorised Plerixafor Accord for mobilizing hematopoietic stem cells in adults with multiple myeloma undergoing autologous stem cell tra…